Advertisement
Included in the AstraZeneca acquisition are the North American rights to aCaptisol(R) enabled budesonide solution (controller medication), a proprietaryshort-acting beta-agonist solution (rescue medication), a customized versionof eFlow(R) (novel aerosol delivery device) for use with both products, andother intellectual property and related assets from Verus.
Advertisement
This is the second acquisition by a large pharmaceutical company wherepurchases have included the licensing of PARI's eFlow in the developmentprogram. In August 2006, Gilead Sciences acquired Corus Pharma for $365million. In December 2006, Gilead Sciences released positive preliminaryresults of their Phase III trial on AIR-CF2, a potential treatment for cysticfibrosis patients that have pulmonary Pseudomonas aeruginosa. These positivepreliminary results were the first Phase III clinical trial resultshighlighting the optimization of drug to device and device to drug with PARI'seFlow, an advanced electronic nebulizer.
About eFlow
eFlow uses a vibrating, perforated membrane that enables extremelyefficient aerosolization of liquid medications. Compared to other nebulizersystems, eFlow can produce aerosols with a very high density of active drug, aprecisely defined droplet size, and a high proportion of respirable dropletsdelivered in the shortest possible amount of time. Combined with its silentmode of operation, small size (it fits in the palm of your hand), lightweight, and battery use, eFlow helps reduce the burden of taking daily-inhaledtreatments.
Due to its efficiency, eFlow is licensed to pharmaceutical companiesduring drug development and for later commercialization so that drug anddevice are optimized together for the final product. This customization iscurrently being utilized in the development of new and improved treatments forcystic fibrosis, asthma, and chronic obstructive pulmonary disease (COPD).
About PARI Pharma
PARI Pharma develops aerosol delivery devices and inhaled therapies.Based on PARI's 100-year history working with aerosols, PARI Pharmaspecializes in treatments for pulmonary and nasal administration optimized toadvanced delivery platforms, such as eFlow.
Focusing on comprehensive inhalation therapy development, includingoptimized nebulizer formulations, analytics, and aerosol characterization,PARI Pharma has several clinical development programs ongoing, eitherpartnered or proprietary. PARI Pharma, a PARI Medical Holding company, islocated in Munich, Germany, with a major presence in the United States.Online at http://www.paripharma.com
SOURCE PARI Pharma
